The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -14.17 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M 7.29 — flag raised, worth a closer lookWatch
- Earnings quality 67/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as BridgeBio Pharma, Inc. reports it. History and quarterly detail are in the app.
- Net product revenue$362.4M
- License and services revenue$128.3M
- Cost of license, services, and royalty revenue$93.8M
- Royalty revenue$11.4M
Leadership changes
From BridgeBio Pharma, Inc.'s own filings, the day they're filed.
- Randal W. Scott · member · departureeff. 2026-06-22
- Neil Kumar · Chief Operating Officer · departureeff. 2024-07-23
Latest filings
- 8-K · Company announcement2026-06-26
- 8-K · Company announcement2026-05-27
- 8-K · Company announcement2026-05-13
- 8-K · Company announcement2026-05-08
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about BridgeBio Pharma, Inc., every answer cited🔒
- The Intelligence Brief — added when BridgeBio Pharma, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.